Gilead maintained at neutral by Merrill

Gilead Sciences Inc. was maintained at a neutral rating by Merrill Lynch analyst Eric Ende. Based on adjusted royalty rate and Tamiflu sales estimates, Merrill is raising its 2006-2007 Tamiflu royalty and earnings per share estimates. The earnings per share estimate is $2.27 from $2.16 in 2006 and to $2.52 from $2.44 in 2007. The analyst's 2008-2010 earnings per share estimates decline, due to the timing of pandemic planning, to $2.61 from $2.69 in 2008, to $2.97 from $3.05 in 2009, and to $3.55 from $3.63 in 2010. Shares of the Foster City, Calif., biopharmaceutical company were up $0.37, or 0.60%, at $61.87 on volume of 2,782,274 shares versus the three-month running average of 3,737,390 shares. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.